Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468656 | 0.85 | ACHE (0.56) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL3896460 | 0.85 | ACHE (0.56) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL4132638 | 0.82 | LMNA (0.53) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL3883831 | 0.80 | ACHE (0.55) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL3883005 | 0.80 | ACHE (0.50) | ACHELMNAALDH1A1HTTTDP1 | |
| Toluene SCHEMBL28188285 | 0.79 | LMNA (0.46) | ACHELMNAALDH1A1HTTKMT2A | |
| SCHEMBL27769975 | 0.79 | TDP1 (0.50) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL3883336 | 0.76 | ACHE (0.46) | ACHELMNAALDH1A1HTTTDP1 | |
| SCHEMBL13937490 | 0.75 | CA4 (0.43) | LMNAHTTTDP1L3MBTL1 | |
| SCHEMBL13916569 | 0.75 | KDM4E (0.44) | ACHELMNAALDH1A1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-9944631-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-17 | — | — | US | disclosed |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | ACHE 1879/4885LMNA 1528/4885ALDH1A1 3912/4885 |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | ACHE 1879/4885LMNA 1528/4885ALDH1A1 3912/4885 |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | ACHE 1879/4885LMNA 1528/4885ALDH1A1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.